Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $8.7 million.

  • Compass Therapeutics' Accumulated Expenses rose 19780.52% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 19780.52%. This contributed to the annual value of $6.3 million for FY2024, which is 15007.96% up from last year.
  • Compass Therapeutics' Accumulated Expenses amounted to $8.7 million in Q3 2025, which was up 19780.52% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Accumulated Expenses registered a high of $13.2 million during Q1 2025, and its lowest value of $1.8 million during Q1 2024.
  • Over the past 3 years, Compass Therapeutics' median Accumulated Expenses value was $7.2 million (recorded in 2024), while the average stood at $6.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 7970.48% in 2024, then skyrocketed by 62804.41% in 2025.
  • Compass Therapeutics' Accumulated Expenses (Quarter) stood at $2.5 million in 2023, then surged by 150.08% to $6.3 million in 2024, then surged by 38.13% to $8.7 million in 2025.
  • Its Accumulated Expenses was $8.7 million in Q3 2025, compared to $11.0 million in Q2 2025 and $13.2 million in Q1 2025.